The following sessions are available either as video/audio webcasts or slides
Wednesday, November 1
Utilizing a PK/PD model to enable design principles within the gantenerumab Phase 3 Graduate program
Rachelle Doody, MD, PhD Roche Product Development Neuroscience, Basel - CH
Higher dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden - Results for the Marguerite and Scarlet Road Open Label Extension Studies
Gregory Klein, PhD Roche Pharma Research and Early Development Clinical Pharmacology and Bioanalytical R&D, Basel - CH
Thursday, November 2
Aducanumab 36-month data from prime: A randomized, double-blind, placebo controlled Phase 1B study in patients with prodromal or mild Alzheimer's disease
Samantha Budd Haeberlein, PhD Biogen, Cambridge, MA - USA
Saturday, November 4
Aducanumab titration dosing regimen: 24-month analysis from prime, a randomized, double-blind, placebo-controlled Phase 1B study in patients with prodromal or Mild Alzheimer's disease
Philipp von Rosenstiel, MD Biogen, Cambridge, MA - USA
The Anti-Aβ Oligomer Drug CT1812 for Alzheimer’s: Phase 1b/2a Safety Trial Outcomes
Lon S Schneider, MD, Keck School of Medicine of USC, Los Angeles, CA, USA
Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer's Disease
Mohammad Afshar, MD, PhD Ariana Pharma, Paris, France
ctad@ant-congres.com